Adverse reaction to immune checkpoint inhibitors
Conditions
Interventions
Case series:N/A
Sponsors
Nanfang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: (1) Voluntary signing of informed consent; (2) At the age of 18-79, with understanding and communication skills; (3) Diagnosed with lung cancer and indications for surgery; (4) Patients without any preoperative treatment for tumor; (5) The postoperative treatment of the patient included immunotherapy; (6) Subject compliance is good, cooperate with follow-up.
Exclusion criteria
Exclusion criteria: (1) Patients with only one course of postoperative immunotherapy; (2) Patients who failed to construct tumor-immune microenvironment organoids; (3) Patients who did not cooperate with follow-up after surgery; (4) Patients who were judged by the investigators to be unfit to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug screen results of tumor-immune microenvironment organoid immune drugs; | — |
Secondary
| Measure | Time frame |
|---|---|
| Test data, imaging data and outcome of irAEs after patients started immunotherapy and at the time of irAEs;Immunotherapy regimen and cycle of patients after radical lung cancer resectioner after radical resection;Survival rate at 2 - year follow-up after initiation of immunotherapy; | — |
Countries
China
Contacts
Public ContactDong Hangming
Nanfang Hospital of Southern Medical Universit
Outcome results
None listed